Sumitomo Pharma America, Inc.
Clinical trials sponsored by Sumitomo Pharma America, Inc., explained in plain language.
US subsidiary of Japanese pharmaceutical company developing treatments for CNS and oncology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill shows promise for rare bone marrow cancer Results expected Apr 2027 (estimated)
- New hope for Hard-to-Treat leukemia? enzomenib trial launches Results expected Jun 2027 (estimated)
-
New pill shows promise for aggressive brain cancer in early trial
Disease control OngoingThis early-phase study tests an oral drug called DSP-0390 in 39 adults whose high-grade glioma (a fast-growing brain tumor) has come back after prior treatment. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must b…
Early phase 1 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Eye disease study seeks better ways to measure sight loss
Knowledge-focused OngoingThis study follows 12 adults with severe retinitis pigmentosa, a genetic eye disease that causes vision loss. Researchers want to find out which vision tests people with very low sight can reliably perform and how their vision changes over one year. The goal is to improve future …
Sponsor: Sumitomo Pharma America, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC